Akebia Therapeutics, Inc. (AKBA) Financial Statements (2026 and earlier)

Company Profile

Business Address 245 FIRST STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments113,37451,87034,01939,49941,96142,925
Cash and cash equivalent113,37451,87034,01939,49941,96142,925
Receivables61,53834,36832,17029,76526,62039,290
Inventory, net of allowances, customer advances and progress billings19,73216,24320,49323,87225,53215,691
Inventory19,73216,24320,49323,87225,53215,691
Other current assets7,9177,3216,2117,3294,8135,754
Other undisclosed current assets 1,2214,0297,22711,63214,01814,489
Total current assets:203,782113,831100,120112,097112,944118,149
Noncurrent Assets
Operating lease, right-of-use asset7,1148,2189,30010,36011,39912,416
Property, plant and equipment1,9042,2002,5332,8953,2653,629
Intangible assets, net (including goodwill)59,04459,04468,05577,06586,07695,086
Goodwill59,04459,04459,04459,04459,04459,044
Intangible assets, net (excluding goodwill)   9,01118,02127,03236,042
Other noncurrent assets38,34137,37727,13417,77911,79312,423
Total noncurrent assets:106,403106,839107,022108,099112,533123,554
TOTAL ASSETS:310,185220,670207,142220,196225,477241,703
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities83,99578,64065,70964,00465,79282,370
Accounts payable12,65815,18013,49410,10711,88214,635
Accrued liabilities71,33763,46052,21553,89753,91067,735
Deferred revenue1,241  43,296695 
Debt      17,500
Other undisclosed current liabilities5,9912,274    
Total current liabilities:91,22780,91465,709107,30066,48799,870
Noncurrent Liabilities
Long-term debt and lease obligation46,51138,69338,35538,03130,14517,183
Long-term debt, excluding current maturities46,51138,69338,35538,03130,14517,183
Liabilities, other than long-term debt14,45713,47213,16515,50062,67861,128
Deferred revenue     43,29643,296
Other liabilities5,1144,7494,7276,5576,7718,885
Operating lease, liability2,1233,5474,9376,2997,6368,947
Derivative instruments and hedges, liabilities7,2205,1763,5012,6444,975 
Other undisclosed noncurrent liabilities133,409136,776140,31593,11993,42594,106
Total noncurrent liabilities:194,377188,941191,835146,650186,248172,417
Total liabilities:285,604269,855257,544253,950252,735272,287
Equity
Equity, attributable to parent24,581(49,185)(50,402)(33,754)(27,258)(30,584)
Common stock222222
Additional paid in capital1,696,8211,629,1671,605,1461,601,7551,599,6691,578,358
Accumulated other comprehensive income666666
Accumulated deficit(1,672,248)(1,678,360)(1,655,556)(1,635,517)(1,626,935)(1,608,950)
Total equity:24,581(49,185)(50,402)(33,754)(27,258)(30,584)
TOTAL LIABILITIES AND EQUITY:310,185220,670207,142220,196225,477241,703

Income Statement (P&L) ($ in thousands)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Revenues57,33646,49737,42843,64832,60756,196
Cost of revenue
(Cost of Product and Service Sold)
(7,625)(20,365)(14,161)(17,047)(11,605)(18,665)
Gross profit:49,71126,13223,26726,60121,00237,531
Operating expenses(36,197)(40,439)(35,772)(35,326)(35,938)(36,157)
Operating income (loss):13,514(14,307)(12,505)(8,725)(14,936)1,374
Nonoperating income (expense)21355(17)(39)95(167)
Loss on contract termination      (825)
Other nonoperating income (expense)21355(17)(39)95658
Interest and debt expense     (517) 
Income (loss) from continuing operations before equity method investments, income taxes:13,727(14,252)(12,522)(8,764)(15,358)1,207
Other undisclosed income (loss) from continuing operations before income taxes(7,615)(8,552)(7,517)182(2,627)(6,556)
Net income (loss):6,112(22,804)(20,039)(8,582)(17,985)(5,349)
Other undisclosed net income attributable to parent      5,963
Net income (loss) available to common stockholders, diluted:6,112(22,804)(20,039)(8,582)(17,985)614

Comprehensive Income ($ in thousands)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Net income (loss):6,112(22,804)(20,039)(8,582)(17,985)(5,349)
Comprehensive income (loss):6,112(22,804)(20,039)(8,582)(17,985)(5,349)
Other undisclosed comprehensive income, net of tax, attributable to parent      5,963
Comprehensive income (loss), net of tax, attributable to parent:6,112(22,804)(20,039)(8,582)(17,985)614

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: